Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with d-Chiro-Inositol

详细信息    查看全文

• 作者：Antonio Simone Laganà ; Luisa Barbaro…
• 关键词：Polycystic Ovary Syndrome ; D ; Chiro ; Inositol ; Ovarian function ; Metabolic factors
• 刊名：Archives of Gynecology and Obstetrics
• 出版年：2015
• 出版时间：May 2015
• 年：2015
• 卷：291
• 期：5
• 页码：1181-1186
• 全文大小：322 KB
• 参考文献：Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81: pp. 19-25
  1. Azziz, R, Woods, KS, Reyna, R, Key, TJ, Knochenhauer, ES, Yildiz, BO (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89: pp. 2745-2749 CrossRef
  2. Norman, RJ, Dewailly, D, Legro, RS, Hickey, TE (2007) Polycystic ovary syndrome. Lancet 370: pp. 685-697 CrossRef
  3. Franks, S, Adams, J, Mason, H, Polson, D (1985) Ovulatory disorders in women with polycystic ovary syndrome. Clin Obstet Gynaecol 12: pp. 605-632
  4. Legro, RS, Kunselman, AR, Dodson, WC, Dunaif, A (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84: pp. 165-169
  5. Nestler, JE, Jakubowicz, DJ (1996) Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 335: pp. 617-623 CrossRef
  6. Nestler, JE, Jakubowicz, DJ (1997) Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 82: pp. 4075-4079
  7. Franks, S (1989) Polycystic ovary syndrome. A changing perspective. Clin Endocrinol (Oxf) 31: pp. 87-120 CrossRef
  8. James, RG, Krakower, GR, Kissebah, AH (1996) Influence of androgenicity on adipocytes and precursor cells in female rats. Obes Res 4: pp. 463-470 CrossRef
  9. Schuring, AN, Schulte, N, Sonntag, B, Kiesel, L (2008) Androgens and insulin–two key players in polycystic ovary syndrome. Recent concepts in the pathophysiology and genetics of polycystic ovary syndrome. Gynakol Geburtshilfliche Rundsch 48: pp. 9-15 CrossRef
  10. Buckler, HM, McLachlan, RI, MacLachlan, VB, Healy, DL, Burger, HG (1988) Serum inhibin levels in polycystic ovary syndrome: basal levels and response to luteinizing hormone-releasing hormone agonist and exogenous gonadotropin administration. J Clin Endocrinol Metab 66: pp. 798-803 CrossRef
  11. Franks, S, Sagle, M, Mason, HD, Kiddy, D (1987) Use of LHRH agonists in the treatment of anovulation in women with polycystic ovary syndrome. Horm Res 28: pp. 164-168 CrossRef
  12. Burghen, GA, Givens, JR, Kitabchi, AE (1980) Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 50: pp. 113-116 CrossRef
  13. Azziz, R (2003) Androgen excess is the key element in polycystic ovary syndrome. Fertil Steril 80: pp. 252-254 CrossRef
  14. Baillargeon, JP, Carpentier, A (2007) Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity. Fertil Steril 88: pp. 886-893 CrossRef
  15. Baptiste, CG, Battista, MC, Trottier, A, Baillargeon, JP (2010) Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol 122: pp. 42-52 CrossRef
  16. González, F, Rote, NS, Minium, J, Kirwan, JP (2006) Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 91: pp. 336-340 CrossRef
  17. Hasegawa, I, Mura
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Gynecology
  Obstetrics and Perinatology
  Endocrinology
  Human Genetics
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0711

文摘

Purpose To evaluate the effects of d-Chiro-Inositol in women affected by polycystic ovary syndrome (PCOS). Methods We enrolled 48 patients, with homogeneous bio-physical characteristics, affected by PCOS and menstrual irregularities. These patients underwent treatment with 1?gr of d-Chiro-Inositol/die plus 400?mcg of Folic Acid/die orally for 6?months. We analyzed pre-treatment and post-treatment BMI, Systolic and Diastolic blood pressure, Ferriman-Gallwey score, Cremoncini score, serum LH, LH/FSH ratio, total and free testosterone, DHEA-S, Δ-4-androstenedione, SHBG, prolactin, glucose/IRI ratio, HOMA index, and resumption of regular menstrual cycles. Results We evidenced a statistically significant reduction of systolic blood pressure, Ferriman-Gallwey score, LH, LH/FSH ratio, total Testosterone, free Testosterone, ?4-Androstenedione, Prolactin, and HOMA Index; in the same patients, we noticed a statistically significant increase of SHBG and Glycemia/IRI ratio. Moreover, we observed statistically significant (62.5?%; p? Conclusions d-Chiro-Inositol is effective in improving ovarian function and metabolism of patients affected by PCOS.